Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
For the detection and quantification of endogenous levels of natural and/or recombinant Mouse CD254 proteins.
LS-F24752 is a 96-well enzyme-linked immunosorbent assay (ELISA) for the Quantitative detection of Mouse TNFSF11 / RANKL / TRANCE in samples of Cell Culture Supernatants, Plasma and Serum. It is based upon a Sandwich assay principle and can be used to detect levels of TNFSF11 / RANKL / TRANCE as low as 10 picograms per milliliter.
All LSBio Custom kits have been predesigned and all necessary components, including antibodies and standards have been identified. Upon receiving a custom kit order, the kit will be assembled and quality control tested before being shipped out. Kit assembly and testing typically takes 4 to 6 weeks. In most cases the final kit is based on the Sandwich assay principle, with a few being Competitive EIA based. Specifications such as Range, Sensitivity, and Precision are defined upon completion. In the event that the custom kit cannot be successfully developed with 6 weeks of the order date, the customer will be notified and the order canceled at no cost.
Cell Culture Supernatants, Plasma, Serum
96-Well Strip Plate
Colorimetric - 450nm (TMB)
62.5 - 4000 pg/ml
Due to their limited shelf life, LSBio ELISA kits are not typically stocked as finished goods. Upon receipt of an order each kit is assembled and tested to ensure that it meets specifications before shipping. Minor changes may occur to the Range, Sensitivity, and Precision. In the event of a significant change the order would be confirmed with the customer before shipping. ELISA kit lot numbers reflect the date of final assembly and testing for each specific kit rather than a bulk manufactured lot. All kits are tested to confirm that they fall within their defined Inter- and Intra- assay coefficient of variation.
Coated 96-well Strip Plate
Biotinylated Detection Antibody (100x)
Avidin-Biotin-HRP Complex (100x)
Biotinylated Detection Antibody Diluent
Avidin-Biotin-HRP Complex Diluent
Wash Buffer (20x)
Adhesive Plate Sealers
Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), is a protein that in humans is encoded by the TNFSF11 gene. This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This gene is mapped to chromosome13q14.11. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. This gene may play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.
Store at 4°C for 6 months or at -20°C for one year. Avoid freeze/thaw cycles.
TNFSF11 / RANKL / TRANCE is a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss.